Schizoaffective Disorder, Schizophrenia, Schizophreniform Disorder
Conditions
Keywords
Donepezil, ECT, Memory Disfunction
Brief summary
This is a double blind randomized investigation of donepezil for patients suffering from schizophrenia, undergoing ECT. Patients will be randomized to receive either donezepil or plasebo, in order to gauge whether donezepil has a protective effect on memory disfunction, while patients are treated with ECT. Several parameters will be invistigated at baseline: general psychopathological measures, memory function scales, side effects scales. The same measurements will be taken throughout the trial and one month after ending the ECT.
Interventions
DRUGDonepezil
Tab.Donepezil 5 mg once daily during ECT treatment and the month after the last ECT treatment
Sponsors
BeerYaakov Mental Health Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Schizophrenia, Schizoaffective disorder, schizophreniform disorder patients who meet criteria for diagnoses by DSM-IV criteria and evaluated by the Structured Clinical Interview for DSM-IV (SCID)
Exclusion criteria
* History of serious neurological disorders including neurodegenerative deseases, mental retardation, substance and/or alcohol dependence. * Pregnant women * Patients who recieved ECT within 6 month * Patients whith contraindication to Donepezil treatment. * Patients with Lithium treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Data will be analyzed using SPSS for Windows. | after 5 ECT treatments |
| Results of the memory and neurocognitive measures will be examined | after 8 ECT treatments |
| using repeated MANOVA with before, within and after ECT treatment. | 1 month after the last ECT treatment |
Countries
Israel
Contacts
Primary ContactTali Nachshoni, MD
Backup ContactMarina Kupchik, MD
Outcome results
None listed